Cancer Survivor at Risk for Second Cancer
Patients who have been cured of a primary cancer may still face the risk of developing a second cancer. This risk can arise due to various factors, including previous treatments and genetic predispositions.
Preventing Second Cancers: Dostarlimab Study
We are studying whether dostarlimab can help prevent second primary cancers in patients who have been cured of their first cancer. This trial will also look at the safety of the treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a history of one or two primary solid tumors that were treated and are currently eligible for curative treatment?
- Are you currently pregnant or breastfeeding?
- Are you taking any immunosuppressive medications like corticosteroids (e.g., Prednisone) or chemotherapy?
- Have you had any major surgery or significant injury in the last 28 days?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Jemperli
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Institut De Cancerologie De L Ouest
Medical oncology
Angers, France
Centre Jean Perrin
Medical Oncology
Beaumont, France
Centre Francois Baclesse
Medical oncology
Caen, France
Sponsor: Centre Leon Berard
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.